Details of the Drug

General Information of Drug (ID: DMOQE91)

Drug Name
RU78191
Synonyms
Phenylmalonic acid; 2613-89-0; 2-Phenylmalonic acid; 2-phenylpropanedioic acid; Propanedioic acid, phenyl-; Phenylmalonicacid; Phenylpropanedioc acid; Malonic acid, phenyl-; RU78191; Propanedioic acid, 2-phenyl-; phenylpropanedioic acid; CHEMBL78794; .alpha.-Carboxyphenylacetic acid; WWYDYZMNFQIYPT-UHFFFAOYSA-N; Toluene-.alpha.,.alpha.-dicarboxylic acid; phenylmalonate; alpha-Carboxyphenylacetic acid; EINECS 220-044-6; Toluene-alpha,alpha-dicarboxylic acid; NSC 41697; NSC 27164; 2-Phenyl-malonic acid; 1o4p; AC1L2PIV
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 180.16
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C9H8O4
IUPAC Name
2-phenylpropanedioic acid
Canonical SMILES
C1=CC=C(C=C1)C(C(=O)O)C(=O)O
InChI
InChI=1S/C9H8O4/c10-8(11)7(9(12)13)6-4-2-1-3-5-6/h1-5,7H,(H,10,11)(H,12,13)
InChIKey
WWYDYZMNFQIYPT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
75791
CAS Number
2613-89-0
DrugBank ID
DB04080
TTD ID
D0R7BX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Src (SRC) DTT SRC 6.45E-01 -0.08 -0.58
Proto-oncogene c-Src (SRC) DTT SRC 2.08E-03 -0.52 -1.62
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
3 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
4 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
9 Clinical pipeline report, company report or official report of Turning Point Therapeutics.